Pain News and Research

Latest Pain News and Research

Signaling molecule involved in osteoarthritis identified

Using naturally-occurring mutant mice with a defective collagen gene, scientists at Harvard have identified a signaling molecule involved in one of the most common causes of disability among the elderly in the United States, osteoarthritis.

4 Jan 2005

Minimally invasive surgery to alleviate the pain and pressure of sinusitis is a safe

Minimally invasive surgery to alleviate the pain and pressure of sinusitis is a safe, effective therapy for geriatric patients who can't be helped by medication alone, according to new research.

3 Jan 2005

New painkiller was discovered in natural form in venomous snails in 1979

The natural form of Prialt – a new drug for severe pain approved this week by the U.S. Food and Drug Administration – was discovered at the University of Utah in 1979 by an incoming freshman studying toxins produced by cone snails.

30 Dec 2004

Economic impact of migraine headaches on American businesses is staggering

With more than 28 million Americans suffering from debilitating migraine headaches each year, employers also suffer through missed days from work and reduced productivity.

30 Dec 2004

People with migraine headaches report more angina, but not more heart disease

People with a history of migraines and other headaches lasting at least four hours are more likely to report suffering from the chest pain doctors call angina than people who do not experience such headaches, a new University of North Carolina at Chapel Hill study concludes.

28 Dec 2004

Lessons learned from troubles with COX-2 inhibitors

One of the nation’s leading cardiovascular medical researchers has issued a call for less aggressive direct-to-consumer advertising and better safety assurances of medications in a special article posted online by JAMA because of its relevance to the recent withdrawals and warning labels on the pain-relieving drugs known as COX-2 inhibitors.

28 Dec 2004

Laser therapy may be considered by arthritis patients as a safe Vioxx alternative

Adverse events of long term medication with NSAIDs and particularly coxibs, has recently received much attention in the Vioxx matter. Consequently, Vioxx has been withdrawn and Prexige has been withheld from the market. The whole group of coxibs, are now under special observation by drug agencies in both Europe and the United States.

27 Dec 2004

Supply problem with the opiate painkiller, diamorphine

The UK Department of Health has advised the NHS that there is a supply problem with the opiate painkiller, diamorphine, and that stocks may rapidly reach a critical level in the next few weeks.

26 Dec 2004

FDA issues not approvable letter to Cellegy Pharmaceuticals

Cellegy Pharmaceuticals has announced receipt of a communication from the U.S. Food and Drug Administration in the form of a Not Approvable Letter for its product Cellegesic(TM) (nitroglycerin ointment).

26 Dec 2004

Public health advisory for the use of non-steroidal anti-inflammatory drug products

The Food and Drug Administration (FDA) has issued a Public Health Advisory summarizing the agency's recent recommendations concerning the use of non-steroidal anti-inflammatory drug products (NSAIDs), including those known as COX-2 selective agents.

23 Dec 2004

Arthritis drug caution advised by New Zealand experts

An expert New Zealand committee reviewing the safety of a group of arthritis drugs called COX-2 inhibitors has reinforced UK advice cautioning against their routine use where safe and effective alternatives are available.

21 Dec 2004

No increased cardiovascular risk seen in elderly patients taking Celebrex

The National Institutes of Health has reported in an Alzheimer's Disease prevention study that there was no increased cardiovascular risk seen in elderly patients taking Celebrex (400 mg daily) for up to three years.

21 Dec 2004

New advice on anti-inflammatory drugs called Cox-2 Inhibitors, including Celebrex

Patients who are taking Celebrex, Bextra and Arcoxia should make a non-urgent appointment with their GP to review their treatment. Patients who have established heart disease or who are at high risk of stroke will have their treatment changed.

21 Dec 2004

FDA issues advice on Naproxen

The FDA has released the following statement on NIH halting a clinical trial involving non-steroidal anti-inflammatory drugs in patients at risk of developing Alzheimer's Disease:

20 Dec 2004

5000 year old system of medicine provides pain relief for people with osteoarthritis of the knee

A 5000 year old system of medicine, acupuncture provides pain relief and improves function for people with osteoarthritis of the knee and serves as an effective complement to standard care.

20 Dec 2004

European market for bone morphogenic proteins in spine fusion

High growth is forecast for novel technologies used either as adjuncts or as alternatives to current surgical procedures for the fusion of spinal vertebrae. Bone morphogenic proteins (BMP) - a new and innovative class of natural growth factors - represent amongst the most exciting of these niches.

20 Dec 2004

Nearly 6 million Americans turned to complementary and alternative medicine because of costs

Nearly 6 million American adults turned to complementary and alternative medicine (CAM) in the past year to treat such conditions as depression and chronic pain because conventional medical treatment was too expensive, according to a national study released today by the Center for Studying Health System Change (HSC).

20 Dec 2004

Advice for patients who have been taking Celebrex or Bextra

The recent announcement that Celebrex, a popular pain drug in the same family as Vioxx, has been found to pose an increased risk of heart problems is bound to leave many pain patients stunned, confused and worried.

20 Dec 2004

Magnetic bracelets reduce pain in osteoarthritis of the hip and knee

Osteoarthritis affects around 760,000 people in the United Kingdom, producing over 3 million general practice consultations in 2000. Manufacturers of magnetic bracelets claim that they can reduce pain and worldwide sales were estimated at £2.6bn ($5bn) in 1999. But evidence about their effectiveness is contradictory.

20 Dec 2004

Celebrex suspension

The National Institutes of Health (NIH) announced that it has suspended the use of COX-2 inhibitor celecoxib (Celebrex™ Pfizer, Inc.) for all participants in a large colorectal cancer prevention clinical trial conducted by the National Cancer Institute (NCI).

19 Dec 2004